Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian D Sanders

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
International Journal of Cardiology|January 29, 2014
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?Sana M Al-Khatib, Joo Y Han, Rex Edwards, et al.
Journal of Cardiovascular Electrophysiology|July 27, 2017
Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT IIEmily P Zeitler, Sana M Al-Khatib, Daniel J Friedman, et al.
JACC. Heart Failure|October 13, 2014
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trialsBenjamin A Steinberg, Sana M Al-Khatib, Rex Edwards, et al.
American Heart Journal|October 12, 2010
Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapiesMelissa H Kong, Eric D Peterson, Gregg C Fonarow, et al.
American Heart Journal|September 11, 2017
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trialsDaniel J Friedman, Sana M Al-Khatib, Emily P Zeitler, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 13, 2014
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trialsPatrick H Pun, Sana M Al-Khatib, Joo Yoon Han, et al.
American Heart Journal|March 13, 2020
Future research prioritization in cardiac resynchronization therapyMarat Fudim, Frederik Dalgaard, Sana M Al-Khatib, et al.
Heart Rhythm|February 19, 2013
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trialsPaul L Hess, Amy Laird, Rex Edwards, et al.
American Heart Journal|June 2, 2007
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac deathSana M Al-Khatib, Gillian D Sanders, J Thomas Bigger, et al.
European Journal of Heart Failure|May 16, 2018
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetesAbhinav Sharma, Sana M Al-Khatib, Justin A Ezekowitz, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
International Journal of Cardiology|January 29, 2014
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?Sana M Al-Khatib, Joo Y Han, Rex Edwards, et al.
Journal of Cardiovascular Electrophysiology|July 27, 2017
Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT IIEmily P Zeitler, Sana M Al-Khatib, Daniel J Friedman, et al.
JACC. Heart Failure|October 13, 2014
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trialsBenjamin A Steinberg, Sana M Al-Khatib, Rex Edwards, et al.
American Heart Journal|October 12, 2010
Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapiesMelissa H Kong, Eric D Peterson, Gregg C Fonarow, et al.
American Heart Journal|September 11, 2017
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trialsDaniel J Friedman, Sana M Al-Khatib, Emily P Zeitler, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 13, 2014
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trialsPatrick H Pun, Sana M Al-Khatib, Joo Yoon Han, et al.
American Heart Journal|March 13, 2020
Future research prioritization in cardiac resynchronization therapyMarat Fudim, Frederik Dalgaard, Sana M Al-Khatib, et al.
Heart Rhythm|February 19, 2013
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trialsPaul L Hess, Amy Laird, Rex Edwards, et al.
American Heart Journal|June 2, 2007
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac deathSana M Al-Khatib, Gillian D Sanders, J Thomas Bigger, et al.
European Journal of Heart Failure|May 16, 2018
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetesAbhinav Sharma, Sana M Al-Khatib, Justin A Ezekowitz, et al.
Pageof 15